(Q36814872)

16 August 2017

1 reference

title

Classical inotropes and new cardiac enhancers (English)

1 reference

16 August 2017

2

Dimitrios Farmakis

1 reference

16 August 2017

John T Parissis

1

1 reference

PubMed ID

17487580

16 August 2017

Markku Nieminen

series ordinal

3

1 reference

16 August 2017

1 June 2007

1 reference

16 August 2017

Heart Failure Reviews

1 reference

16 August 2017

12

1 reference

16 August 2017

2

1 reference

16 August 2017

149-156

1 reference

https://scigraph.springernature.com/pub.10.1007/s10741-007-9014-5

16 August 2017

0 references

cites work

Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10741-007-9014-5

The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis

21 January 2018

1 reference

12 December 2020

Hemodynamic effect of intracoronary administration of levosimendan in the anesthetized pig.

1 reference

12 December 2020

Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure

1 reference

12 December 2020

Inotropic therapy for heart failure: an evidence-based approach.

1 reference

12 December 2020

Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure

1 reference

12 December 2020

Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake

1 reference

12 December 2020

Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators

1 reference

12 December 2020

Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology

1 reference

12 December 2020

Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure

1 reference

12 December 2020

Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial

1 reference

12 December 2020

Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients

1 reference

12 December 2020

Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.

1 reference

12 December 2020

Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).

1 reference

12 December 2020

Management of acute decompensated heart failure: treatment, controversy, and future directions

1 reference

12 December 2020

The challenge of acute decompensated heart failure

1 reference

12 December 2020

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

1 reference

12 December 2020

Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.

1 reference

12 December 2020

Randomized clinical trials with levosimendan

1 reference

12 December 2020

Levosimendan for the treatment of acute heart failure syndromes

1 reference

12 December 2020

Evidence-based use of levosimendan in different clinical settings

1 reference

12 December 2020

Cardioprotection: a new paradigm in the management of acute heart failure syndromes

1 reference

12 December 2020

Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.

1 reference

12 December 2020

Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure

1 reference

12 December 2020

Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST).

1 reference

12 December 2020

Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).

1 reference

12 December 2020

Pharmacological mechanisms contributing to the clinical efficacy of levosimendan

1 reference

12 December 2020

Acute heart failure associated with high admission blood pressure - A distinct vascular disorder?

1 reference

12 December 2020

A rational approach for the treatment of acute heart failure: current strategies and future options

1 reference

12 December 2020

Hibernating myocardium: an incomplete adaptation to ischemia

1 reference

12 December 2020

Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry

1 reference

12 December 2020

The search for the ideal positive inotropic agent

1 reference

12 December 2020

1 reference

12 December 2020

Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy

1 reference

12 December 2020

Current insights into the modern treatment of decompensated heart failure

1 reference

12 December 2020

10.1007/S10741-007-9014-5

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17487580